EMPagliflozin After Aortic Valve Replacement

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

Also called NCT06171802

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 206 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06171802
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06171802. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-14 (actual); primary completion 2026-05-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EMPagliflozin After Aortic Valve Replacement
Acronym
EMPAVR
Condition
Aortic Valve Stenosis
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Copenhagen University Hospital, Rigshospitalet (class: other)

Record details

Record id
cardio:ct-nct06171802
Content hash
d050e93b3e60ae9901e685d2fd30de24f82c3516758a2e6ffc49fd678e5497e6